Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Anti-digoxin polyclonal antibody - AMAG Pharmaceuticals/Glenveigh Pharmaceuticals

Drug Profile

Anti-digoxin polyclonal antibody - AMAG Pharmaceuticals/Glenveigh Pharmaceuticals

Alternative Names: AMAG-423; Anti-digoxin-polyclonal-antibody-DigiFab; Anti-digoxin-polyclonal-antibody-DigiTAb; DIF; DigiBind; DigiFab; Digoxin Immune Fab; Digoxin Immune Fab (Ovine)

Latest Information Update: 21 Aug 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Glenveigh Pharmaceuticals; Protherics
  • Developer BTG; Velo Bio
  • Class Antidotes; Immunoglobulin fragments; Polyclonal antibodies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Preeclampsia
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Poisoning
  • Phase II/III Preeclampsia

Most Recent Events

  • 19 Aug 2019 BTG has been acquired by Boston Scientific Corporation
  • 03 Oct 2018 Anti-digoxin polyclonal antibody licensed to AMAG Pharmaceuticals worldwide for Preeclampsia
  • 26 Sep 2018 AMAG Pharmaceuticals announces intention to submit an NDA to the US FDA for Preeclampsia in the second half of 2020
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top